Metformin/rosiglitazone

An inhibitor of Dkk1 that activates the Wnt signaling pathway, stimulating &beta-catenin/TCF-dependent transcription with an EC₅₀ value of 0.63 &microM has good pharmacokinetic properties and increases trabecular bone formation in

An inhibitor of Dkk1 that activates the Wnt signaling pathway, stimulating &beta-catenin/TCF-dependent transcription with an EC₅₀ value of 0.63 &microM has good pharmacokinetic properties and increases trabecular bone formation in

VEGF stimulators: autophagy inhibiting agent: inhibitors of platelet aggregation:.

inhibitors of the c-Jun N-terminal kinase.

Potent and selective σ1 receptor antagonist: activein vivo.

Potent and selective σ1 receptor antagonist: activein vivo.

Potent and selective σ1 receptor antagonist: activein vivo.

Potent and selective σ1 receptor antagonist: activein vivo.

Potent and selective σ1 receptor antagonist: activein vivo.

WS6 is a compound that stimulates the proliferation of pancreatic &beta cells in rodent and human primary islets (EC_max = 200 and 400 nM, respectively, over four days). It promotes &beta cell growth in vivo, increasing &beta cell mass

WS6 is a compound that stimulates the proliferation of pancreatic &beta cells in rodent and human primary islets (EC_max = 200 and 400 nM, respectively, over four days). It promotes &beta cell growth in vivo, increasing &beta cell mass

WS6 is a compound that stimulates the proliferation of pancreatic &beta cells in rodent and human primary islets (EC_max = 200 and 400 nM, respectively, over four days). It promotes &beta cell growth in vivo, increasing &beta cell mass